Home / Biosimilars

Biosimilars

News

22119008_l LG Chem gains approval for adalimumab biosimilar in Japan posted 04/05/2021

Japan-based LG Chem (formerly LG Life Sciences) announced on 23 March 2021 in a public filing that it had received approval f...

EC approval for bevacizumab biosimilar Alymsys/Oyavas posted 04/05/2021

The European Commission (EC) granted marketing authorization for the bevacizumab biosimilar Alymsys/Oyavas (MB02), on 31 Marc...

Advances for Formycon and Alteogen’s eye disease biosimilar candidates posted 04/05/2021

In March 2021, Formycon confirmed the resubmission strategy for their Lucentis® (ranibizumab) biosimilar candidate (FYB2010)...

FDA accepts application for adalimumab biosimilar CHS-1420 posted 04/05/2021

US-based Coherus BioSciences (Coherus) announced on 17 February 2021 that the US Food and Drug Administration (FDA) had accep...

Australian and Indian approval for teriparatide products posted 04/05/2021

Australia’s drug regulatory agency, the Therapeutic Goods Administration (TGA), has approved a teriparatide biosimilar and th...

 

Research

A positive outlook for the US biosimilars market posted 06/05/2021

The US is keeping pace with the European pioneers of biosimilars approvals, reveals an article published in GaBI Journal [1].

Expanding access to trastuzumab biological treatments posted 06/05/2021

The anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab is indicated for treatment of HER2-p...

CADTH summarizes evidence on switching to etanercept biosimilars posted 06/05/2021

The Canadian Coordinating Office for Health Technology Assessment (CCOHTA), known today as CADTH, is an independent, not-for-...

Relieving the economic burden on EU healthcare budgets: spotlight on IV trastuzumab and rituximab biosimilars posted 30/04/2021

In an ageing society with increasing medical need, biological treatments have played a key role in reforming the management o...

Characteristics associated with biosimilar use in Medicare recipients posted 23/04/2021

What patient, physician and practice characteristics are associated with biosimilar usage for the biologicals filgrastim and...

 

General

Rheumatoid arthritis treatments in Australia posted 05/05/2021

Analysis of the treatment landscape for rheumatoid arthritis in Australia shows that AbbVie’s Humira (adalimumab) and Pfizer’...

Biosimilars of enoxaparin sodium posted 23/04/2021

Enoxaparin sodium is an anticoagulant medication (blood thinner). It is used to treat and prevent deep vein thrombosis (DVT)...

Switching V19A17 British Columbia adds adalimumab to biosimilar switching programme posted 23/04/2021

British Columbia (BC), the first province in Canada to switch patients to biosimilar drugs, has added adalimumab to its switc...

Biosimilars of ustekinumab posted 23/04/2021

Ustekinumab is a humanized monoclonal antibody that interferes with the triggering of the body’s inflammatory response throug...

Biosimilars of aflibercept posted 23/04/2021

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor. It is indicated for the treatment of neovascular (wet)...

Generics News Research General

more

Biosimilars News Research General

more